CORT Corcept Therapeutics
- 28.640
- -0.240-0.83%
Corcept Therapeutics News
Corcept Therapeutics Incorporated's (NASDAQ:CORT) 26% Jump Shows Its Popularity With Investors
The Corcept Therapeutics Incorporated (NASDAQ:CORT) share price has done very well over the last month, posting an excellent gain of 26%. Taking a wider view, although not as strong as the last mon
Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing
Sean Maduck, President, Corcept Endocrinology, on May 13, 2024, sold 50,000 shares in Corcept Therapeutics (CORT) for $1,400,000. Following the Form 4 filing with the SEC, Maduck has control over a to
Corcept Therapeutics(CORT.US) Officer Sells US$1.4 Million in Common Stock
$Corcept Therapeutics(CORT.US)$ Officer Maduck Sean sold 50,000 shares of common stock on May 13, 2024 at an average price of $28 for a total value of $1.4 million.Source: Announcement What is stateme
Corcept Therapeutics(CORT.US) Officer Sells US$187.9K in Common Stock
$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 7,227 shares of common stock on May 9, 2024 at an average price of $26 for a total value of $187.9K.Source: Announcement What is statem
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 1.35 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Corcept Therapeutics(CORT.US)$ Officer Maduck Sean intends to sell 50,000 shares of its common stock on May 13, with a total market value of approximately $1.35 millio
10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 127K in Common Stocks
SEC FILLINGS DISCLOSED/ May 9, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on May 9, with a total market value of approximately $127K.
Corcept Therapeutics(CORT.US) Officer Sells US$281.58K in Common Stock
$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 10,830 shares of common stock on May 2, 2024 at an average price of $26 for a total value of $281.58K.Source: Announcement What is stat
Corcept Therapeutics(CORT.US) Director Sells US$50,798 in Common Stock
$Corcept Therapeutics(CORT.US)$ Director Swisher Daniel N JR sold 2,200 shares of common stock on May 1, 2024 at an average price of $23.09 for a total value of $50,798.Source: Announcement What is st
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $40
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics with a Buy and raises the price target from $38 to $40.
Corcept Therapeutics Price Target Raised to $44.00/Share From $42.00 by Truist Securities
Corcept Therapeutics Price Target Raised to $44.00/Share From $42.00 by Truist Securities
Corcept Therapeutics Is Maintained at Buy by Truist Securities
Corcept Therapeutics Is Maintained at Buy by Truist Securities
Earnings Call Summary | Corcept Therapeutics(CORT.US) Q1 2024 Earnings Conference
The following is a summary of the Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript:Financial Performance:Corcept Therapeutics reported Q1 2024 revenues of $146.8 million, a 39
Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating
Corcept Therapeutics (CORT) has an average rating of buy and price targets ranging from $35 to $61, according to analysts polled by Capital IQ. Price: 26.15, Change: +2.27, Percent Change: +9.51
Q1 2024 Corcept Therapeutics Inc Earnings Call
Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024
Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.
Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.
Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est
Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, Vs. Street Est of $0.22
04:12 PM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22
Analysis
Price Target
No Data
